Eli Lilly & financials
$1,184.63−0.01%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $22.32B | $21.49B | $19.97B | $21.22B |
| Gross profit | $54.13B | $36.63B | $27.04B | $21.91B | $21.01B | $19.06B | $17.60B | $16.81B | $15.53B | $15.51B |
| Gross margin | 83.0% | 81.3% | 79.2% | 76.8% | 74.2% | 77.7% | 78.8% | 78.2% | 77.7% | 73.1% |
| Operating income | $26.30B | $12.90B | $6.46B | $7.13B | $6.36B | $6.06B | $4.97B | $3.53B | $2.00B | $3.26B |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B | -$204.1M | $2.74B |
| Net margin | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% | 15.0% | −1.0% | 12.9% |
| Diluted EPS | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 | $6.79 | $8.89 | $3.13 | $-0.19 | $2.58 |
| EBITDA | $31.69B | $18.81B | $11.85B | $9.80B | $9.19B | $7.51B | $6.78B | $5.41B | $4.90B | $5.14B |
| Operating cash flow | $16.81B | $8.82B | $4.24B | $6.45B | $6.70B | $6.50B | $4.84B | $5.52B | $5.62B | $4.80B |
| Free cash flow | $8.97B | $3.76B | $792.0M | $4.60B | $5.39B | $4.47B | $3.80B | $4.31B | $4.54B | $3.76B |
| Diluted shares | 899.3M | 904.1M | 903.3M | 904.6M | 911.7M | 912.5M | 935.7M | 1,033.7M | 1,052.0M | 1,061.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B | $3.66B |
| Short-term investments | $0.00 | $0.00 | $109.1M | $144.8M | $90.1M | $24.2M |
| Total debt | $42.50B | $33.64B | $25.23B | $25.02B | $23.73B | $16.60B |
| Total assets | $112.48B | $78.72B | $64.01B | $49.49B | $48.81B | $46.63B |
| Total liabilities | $85.94B | $64.44B | $53.14B | $38.71B | $39.65B | $40.81B |
| Shareholders' equity | $26.54B | $14.27B | $10.86B | $10.78B | $9.15B | $5.83B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology